Dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment.

Clinical Sarcoma Research Pub Date : 2018-12-14 eCollection Date: 2018-01-01 DOI:10.1186/s13569-018-0110-1
Johnathan R Lex, Scott Evans, Jonathan D Stevenson, Michael Parry, Lee M Jeys, Robert J Grimer
{"title":"Dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment.","authors":"Johnathan R Lex,&nbsp;Scott Evans,&nbsp;Jonathan D Stevenson,&nbsp;Michael Parry,&nbsp;Lee M Jeys,&nbsp;Robert J Grimer","doi":"10.1186/s13569-018-0110-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Dedifferentiated chondrosarcomas (CS) are a high-grade variant of CS that confers a 5-year survival of around 10-24%. Dedifferentiated CS arising from the pelvis confers an even worse prognosis.</p><p><strong>Questions: </strong>(1) What is the prognosis of patients with dedifferentiated CS of the pelvis? (2) Do wide margins or type of surgical intervention influence outcome? (3) Does the use of adjuvant therapy affect outcome?</p><p><strong>Methods: </strong>Patients were retrospectively reviewed from a prospectively collated musculoskeletal oncology database from 1995 to 2016. Thirty-one cases of dedifferentiated CS arising from the pelvis were included. Wide margins were defined as greater than 4 mm. The mean age was 55.6 years (range 33 to 76 years) and there were 19 males (61.3%) and 12 females (38.7%).</p><p><strong>Results: </strong>The disease presented at a locally or systemically advanced stage in 13 patients (41.9%). Eighteen patients (58.1%) underwent surgery with curative intent. Overall survival at 12 months was 15.4% for patients treated with palliative intent and 50% for those treated with surgery. In the surgical group, there were higher rates of disease-free survival in patients who underwent hindquarter amputation and those who received wide surgical margins (p = 0.047 and p = 0.019, respectively). Those who underwent hindquarter amputation were more likely to achieve wide margins (p = 0.05). Time to recurrent disease (local or systemic) was always less than 24 months. No hindquarter amputation for recurrent disease resulted in disease-free survival. No patient who received adjuvant therapy for palliative or recurrent disease had disease control.</p><p><strong>Conclusions: </strong>Pelvic dedifferentiated CS often presents at an advanced local or systemic stage and confers a poor prognosis. Achieving wide surgical margins (> 4 mm) provided the highest rate of long-term disease-free survival. Failing to achieve wide margins results in rapid disease recurrence, conferring deleterious consequences.</p>","PeriodicalId":10684,"journal":{"name":"Clinical Sarcoma Research","volume":"8 ","pages":"23"},"PeriodicalIF":0.0000,"publicationDate":"2018-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13569-018-0110-1","citationCount":"22","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Sarcoma Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13569-018-0110-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 22

Abstract

Background: Dedifferentiated chondrosarcomas (CS) are a high-grade variant of CS that confers a 5-year survival of around 10-24%. Dedifferentiated CS arising from the pelvis confers an even worse prognosis.

Questions: (1) What is the prognosis of patients with dedifferentiated CS of the pelvis? (2) Do wide margins or type of surgical intervention influence outcome? (3) Does the use of adjuvant therapy affect outcome?

Methods: Patients were retrospectively reviewed from a prospectively collated musculoskeletal oncology database from 1995 to 2016. Thirty-one cases of dedifferentiated CS arising from the pelvis were included. Wide margins were defined as greater than 4 mm. The mean age was 55.6 years (range 33 to 76 years) and there were 19 males (61.3%) and 12 females (38.7%).

Results: The disease presented at a locally or systemically advanced stage in 13 patients (41.9%). Eighteen patients (58.1%) underwent surgery with curative intent. Overall survival at 12 months was 15.4% for patients treated with palliative intent and 50% for those treated with surgery. In the surgical group, there were higher rates of disease-free survival in patients who underwent hindquarter amputation and those who received wide surgical margins (p = 0.047 and p = 0.019, respectively). Those who underwent hindquarter amputation were more likely to achieve wide margins (p = 0.05). Time to recurrent disease (local or systemic) was always less than 24 months. No hindquarter amputation for recurrent disease resulted in disease-free survival. No patient who received adjuvant therapy for palliative or recurrent disease had disease control.

Conclusions: Pelvic dedifferentiated CS often presents at an advanced local or systemic stage and confers a poor prognosis. Achieving wide surgical margins (> 4 mm) provided the highest rate of long-term disease-free survival. Failing to achieve wide margins results in rapid disease recurrence, conferring deleterious consequences.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
骨盆去分化软骨肉瘤:临床结果和目前的治疗。
背景:去分化软骨肉瘤(CS)是CS的一种高级别变体,其5年生存率约为10-24%。发生于骨盆的去分化CS的预后更差。问题:(1)骨盆去分化CS患者预后如何?(2)切缘宽或手术干预类型会影响预后吗?(3)辅助治疗是否影响预后?方法:回顾性分析1995年至2016年前瞻性整理的肌肉骨骼肿瘤学数据库中的患者。31例发生于骨盆的去分化CS。宽边距定义为大于4毫米。平均年龄55.6岁(33 ~ 76岁),男性19例(61.3%),女性12例(38.7%)。结果:13例(41.9%)患者表现为局部或全身性晚期。18例患者(58.1%)接受手术治疗。接受姑息治疗的患者12个月总生存率为15.4%,接受手术治疗的患者为50%。在手术组中,后肢截肢患者的无病生存率高于宽手术切缘患者(p = 0.047和p = 0.019)。后肢截肢的患者更有可能获得较大的切缘(p = 0.05)。复发时间(局部或全身)均少于24个月。复发性疾病无后肢截肢导致无病生存。接受姑息性或复发性疾病辅助治疗的患者均无疾病控制。结论:盆腔去分化CS常出现在局部或全身晚期,预后较差。获得较宽的手术切缘(> 4mm)提供了最高的长期无病生存率。未能获得广泛的边缘导致疾病迅速复发,从而产生有害的后果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊介绍: Clinical Sarcoma Research considers for publication articles related to research on sarcomas, including both soft tissue and bone. The journal publishes original articles and review articles on the diagnosis and treatment of sarcomas along with new insights in sarcoma research, which may be of immediate or future interest for diagnosis and treatment. The journal also considers negative results, especially those from studies on new agents, as it is vital for the medical community to learn whether new agents have been proven effective or ineffective within subtypes of sarcomas. The journal also aims to offer a forum for active discussion on topics of major interest for the sarcoma community, which may be related to both research results and methodological topics.
期刊最新文献
Partial response to erlotinib in a patient with imatinib-refractory sacral chordoma. Locally recurrent extraskeletal myxoid chondrosarcoma of the shoulder: a case of complete neoadjuvant radiotherapy response. The role of prognostic nutritional index in the management of pulmonary sarcomatoid carcinoma. Ifosfamide-induced encephalopathy: the EEG with frontal intermittent delta activity, and rapid resolution with methylene blue: A case report. Simultaneous diagnosis of liver PEComa in a family with known Li-Fraumeni syndrome: a case report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1